Ovarian Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Comparing First-line Therapies for Mucinous Ovarian or Fallopian Tube Cancer
(Posted: 01/11/2011) - In this trial, which is being conducted in both the United States and the United Kingdom, women with stage II to IV or recurrent stage I mucinous epithelial ovarian or fallopian tube cancer will be randomly assigned to receive either paclitaxel/carboplatin with or without bevacizumab or oxaliplatin/capecitabine with or without bevacizumab.
- Optimizing Chemotherapy with Bevacizumab for Ovarian Cancer
(Posted: 02/09/2010) - In this trial, patients with stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cancer will be randomly assigned to receive one of three regimens using intravenous or intravenous and intraperitoneal chemotherapy in addition to bevacizumab.
- Targeted Therapy for Ovarian Cancer
(Posted: 10/31/2006, Updated: 01/06/2010) - In this trial, women who have undergone initial surgery for ovarian cancer or primary peritoneal cancer will receive standard intravenous chemotherapy and some will receive additional treatment with bevacizumab.
- Testing a New Drug in Advanced BRCA-related Cancer
(Posted: 09/08/2009) - In this clinical trial, women with advanced breast or ovarian cancer who carry a known BRCA gene mutation or who have a strong family history of these diseases (and are, therefore, likely to carry such a mutation) will be treated with a new drug called AZD2281 (olaparib) together with the chemotherapy drug carboplatin.
- Targeted Treatment for Advanced Solid Tumors
(Posted: 12/16/2008) - This clinical trial combines the drug dasatinib with the angiogenesis inhibitor bevacizumab for patients with metastatic or unresectable solid tumors.